Dr Link is a CSIC researcher at Institute of Biomedical Research Alberto Sols (Madrid) focused on drug resistance mechanisms in cancer. He is also group leader at the Algarve Biomedical Center Research Institute (ABC-RI), and holds a position as an invited assistant professor at the Faculdade de Medicina e Ciências Biomédicas (FMBC) at the Universidade do Algarve (UAlg) in Faro and professor honorário at the Universidad Autónoma, Madrid (UAM). He is co-founder of Refoxy Pharma GMBH, Berlin/Boston, a biotech company dedicated to target FOXO proteins (www.refoxy.com). Dr Link counts with more than 25 years of experience in basic and translational biomedical research. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 11 as first author, over 40 as senior author. He published articles (selection) in Nature, Oncogene, PNAS, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology, Trends in Pharmacological Sciences, Drug Resistance Updates and Aging Cell. His work has been cited 6478 times. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH, AIFA (Italy), University of Macau (China), HRC (New Zealand). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Importantly, the Link group was one of the first to identify CRM1 inhibitors and ever since was on the forefront of CRM1 drug discovery. He identified TRIB2 as an oncogene involved in therapy resistance. Dr Link obtained his PhD degree from the University of Hamburg, followed by a postdoc at CNB, Madrid before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2012, he accepted a position as an assistant professor at the UAlg, Faro, Portugal where he was head of the Department of Oncobiology and director of the Masters program on Molecular mechanisms of cancer. In 2018, he also joined the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) in Madrid, Spain as a CSIC researcher and group leader. Five greatest contributions to science: 1. Cloning of Arg3.1/ARC, one of the most important genes in neuroscience and synaptic plasticity (Proc. Natl. Acad. Sci. USA 92, 5734-5738. doi: 10.1073/pnas.92.12.5734) 2. Cloning of DREAM, the first transcription factor directly regulated by calcium (Nature, 398, 80-84. doi: 10.1038/18044) 3. Identifying genetic and pharmacological means to activate FOXO transcription factors considered as key tumor suppressors and longevity genes (Nature Reviews Drug Discovery 20, 21-38. doi: 10.1038/s41573-020-0088-2) 4. Characterizing TRIB2 as an oncogene in Melanoma that confers therapy resistance (Nature Comm. 8, 14687. doi: 10.1038/ncomms14687) 5. Generating high content screening (HCS) technology to identify CRM1 inhibitors (Trends Biotechnol. 28, 237-245. (Title story + Cover art) doi: 10.1016/j.tibtech.2010.02.005)